Data from 2 studies, LIGHTHOUSE and SPOTLIGHT, have shown the benefit of flotufolastat F 18 injection as a radiohybrid PSMA-targeted PET imaging agent in prostate cancer. The agent has now been added ...
Credit: Blue Earth Diagnostics. The approval was based on data from the LIGHTHOUSE and SPOTLIGHT clinical trials. The Food and Drug Administration (FDA) has approved Posluma ® (flotufolastat F 18) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results